KLYV THERAPEUTICS AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

CEO: MV
Maria Vistnes1983
Chairman of the board: AB
Andreas Berg1965
Years since formation: 1 year; since Oct 24, 2023
Type: Limited company
VAT registered: No
Number of employees: 0

Ownership

Number of shares and share classes: 100,000; 1 share class
Total number of shareholders: 2; companies
Belongs to group of

Financials

Annual total result 2023: -2; NOK
Total equity 2023: 94,429; NOK

Last update: Aug 29, 2024

Management

Management / administration

Name	Role	Shares
MV Maria Vistnes 1983	Managing Director/CEO	40 % indirectly

Board

Name	Role	Shares
AB Andreas Berg 1965	Chairman	20 % indirectly
MV Maria Vistnes 1983	Board Member	40 % indirectly
BL Beret Luise Sundet 1967	Board Member	-
TS Torkild Stenbock 1972	Board Member	-

Others

Name	Role	Shares
S SPAREBANK 1 REGNSKAPSHUSET SØRØST-NORGE AS	Accountant	-

Top 10 individual shareholders

Name	Role	Shares
JR Jon Riise 1982	-	40 % indirectly
MV Maria Vistnes 1983	Managing Director/CEO, Board Member	40 % indirectly
AB Andreas Berg 1965	Chairman	20 % indirectly

Last update: Apr 25, 2024

Ownership

Company shareholders

Name	Share class	Number of shares	Share
S SPRINGHEART HOLDING AS	Ordinary shares	80,000	80 %
T TAILORMADE INVEST AS	Ordinary shares	20,000	20 %

Last update: May 24, 2024

Group structure

SPRINGHEART HOLDING AS
Total operating income 2023: NOK 0
Operating profit 2023: NOK -13,509
Employees: 0

Financials

in NOK

Summary

Year	2023
Total operating income	0
Annual Total Result	-2
Total assets	94,429
Total liabilities	0
Total equity	94,429

P&L

Year	2023
Total operating income	0
Total operating costs	2
Operating result	-2
Financial income/costs	0
Profit before tax	-2
Total tax & extraordinary income/cost	0
Annual Total Result	-2

Balance overview

Year	2023
Total fixed assets	0
Total current assets	94,429
Total assets	94,429
Short term debt	0
Long term debt	0
Total liabilities	0
Contributed capital	94,430
Retained earnings	-2
Total equity	94,429
Total equity and liabilities	94,429

KLYV THERAPEUTICS AS832 316 032